GLP Capital Partners Inc (“GCP US”) is a registered investment adviser that primarily focuses on uncovering advantaged opportunities in logistics, data centers, renewable energy, self-storage and related technologies. GCP US is part ofGLP Capital Partners (“GCP”), a leading global alternative ...
`` We are very excited to expand our relationship with GLP Capital Partners and partner with them as they launch their new Industrial Fund , '' said Jason Sheller , CBRE Group , Inc. 's Global Head of Business Development and Strategy . ...
首发主承销商KeyBanc Capital Markets,Lehman Brothers Inc 货币单位USD 公司名称Global Partners LP 注册地址美国特拉华州 办公地址P.O. Box 9161, 800 South Street, Waltham, Massachusetts, USA 成立日期2005-03 董事会主席Richard Slifka 公司属地United States 美国 ...
These strengths drive its success and differentiate it from its peers: ‰ Disciplined investor with a proven track record of growing organically and via acquisitions ‰ Global fund manager with a track record of raising capital and strong, long-term relationships with capital partners 1 ‰ Prudent...
原有投资方也参与了此轮融资,包括Eight Roads、F-Prime Capital Partners、启明创投、红杉资本中国、TF Capital和药明康德。 2022年4月,完成一轮3300万美元的超额认购融资。由新投资者Deep Track Capital和Piper Heartland Healthcare Capital投资。 2022年2月,硕迪生物宣布推出全资子公司—倍勘生物(Basecamp Bio),以...
原有投资方也参与了此轮融资,包括Eight Roads、F-Prime Capital Partners、启明创投、红杉资本中国、TF Capital和药明康德。 2022年4月,完成一轮3300万美元的超额认购融资。由新投资者Deep Track Capital和Piper Heartland Healthcare Capital投资。 2022年2月,硕迪生物宣布推出全资子公司—倍勘生物(Basecamp Bio),以...
原有投资方也参与了此轮融资,包括Eight Roads、F-Prime Capital Partners、启明创投、红杉资本中国、TF Capital和药明康德。 2022年4月,完成一轮3300万美元的超额认购融资。由新投资者Deep Track Capital和Piper Heartland Healthcare Capital投资。 2022年2月,硕迪生物宣布推出全资子公司—倍勘生物(Basecamp Bio),以...
I think going forward, it all depends on where we are in our capital allocation and what we think the best return of capital is to unitholders. We've got an acquisition that we've inked in December that we think is a great one for the partnership on the Gulf acquisition. And so I ...
2021年7月,硕迪生物完成由BVF Partners领投的1亿美元B轮融资,每股$4.0483。其他新投资方包括Casdin Capital、Cormorant Asset Management、Janus Henderson Investors、Lilly Asia Ventures、Monashee Capital、Sage Partners、Stork Capital、Surveyor Capital、TCG X、Terra Magnum Capital Partners、Woodline Partners LP,以...
GLP1 PGTx: 一种GLP-1R调节剂药物,由Fractyl Health, Inc. (弗拉克泰尔实验室公司)公司最早进行研发,目前全球最高研发状态为临床前,作用机制: GLP-1R调节剂(胰高血糖素样肽-1调节剂),治疗领域: 内分泌与代谢疾病,在研适应症: 2型糖尿病,肥胖,在研机构: Fractyl Health